Chronic obstructive pulmonary disease (COPD) is a heterogeneous and progressive lung condition representing a leading cause of morbidity and mortality worldwide. Despite advances in COPD management, many patients continue to experience recurrent exacerbations and persistent disease burden.
At the American Thoracic Society (ATS) International Conference, Monica Kraft, Icahn School of Medicine at Mount Sinai, New York City, New York, USA, examined the biology of interleukin-33 (IL-33) and its role in the pathobiology of COPD.
